Cannapharmarx, Inc. (CPMD) — SEC Filings
Cannapharmarx, Inc. (CPMD) — 17 SEC filings. Latest: 8-K (Dec 18, 2025). Includes 8 8-K, 6 10-Q, 2 10-K.
View Cannapharmarx, Inc. on SEC EDGAR
Overview
Cannapharmarx, Inc. (CPMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: CANNAPHARMARX, INC. reported a significant increase in revenue for the nine months ended September 30, 2025, reaching $1,223,533, up from $338,003 in the prior year, representing a 262% increase. Despite this revenue growth, the company's net loss widened to $3,581,863 for the nine months ended Sept
Sentiment Summary
Across 17 filings, the sentiment breakdown is: 2 bearish, 15 neutral. The dominant filing sentiment for Cannapharmarx, Inc. is neutral.
Filing Type Overview
Cannapharmarx, Inc. (CPMD) has filed 8 8-K, 6 10-Q, 2 10-K, 1 8-K/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (17)
Risk Profile
Risk Assessment: Of CPMD's 15 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,223,533 |
| Net Income | $(3,581,863) |
| Cash Position | $927 |
Key Executives
- Elliot Zemel
Industry Context
The cannabis industry continues to evolve with increasing competition and regulatory scrutiny. Companies are focused on scaling operations, improving cultivation efficiency, and navigating complex market access. However, many smaller players struggle with profitability and access to capital, especially those facing regulatory hurdles or operational challenges.
Top Tags
financials (5) · 10-Q (4) · pharmaceuticals (4) · Cannabis Industry (2) · Regulatory Risk (2) · Liquidity Crisis (2) · Going Concern (2) · Cease Trade Order (2) · 8-k (2) · management-change (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue for nine months ended Sept 30, 2025 | $1,223,533 | Increased from $338,003 in 2024, a 262% increase |
| Net loss for nine months ended Sept 30, 2025 | $(3,581,863) | Widened from $(6,164,948) in 2024 |
| Gross loss for nine months ended Sept 30, 2025 | $(1,563,817) | Increased from $(1,244,023) in 2024 |
| Cash at September 30, 2025 | $927 | Decreased from $2,156 at December 31, 2024, indicating severe liquidity issues |
| Total current liabilities at September 30, 2025 | $28,480,524 | Increased from $25,752,496 at December 31, 2024 |
| Common shares outstanding as of November 14, 2025 | 662,501,405 | High share count for a company with significant losses |
| Loss on impairment of inventory for nine months ended Sept 30, 2025 | $1,506,292 | Included in cost of goods sold, indicating inventory valuation challenges |
| Current portion of loans payable to related parties at September 30, 2025 | $11,885,572 | Significantly increased from $462,818 at December 31, 2024, highlighting reliance on related party financing |
| Revenue for six months ended June 30, 2025 | $566,927 | Increased from $25,839 in prior year, showing significant growth in cannabis sales. |
| Net loss for six months ended June 30, 2025 | $2,104,052 | Improved from $6,353,369 net loss in 2024, but still a substantial loss. |
| Gross loss for six months ended June 30, 2025 | $1,123,817 | Widened from $887,865 in 2024, indicating high production costs relative to revenue. |
| Cash as of June 30, 2025 | $16,975 | Increased from $2,156 at December 31, 2024, but remains critically low. |
| Working capital deficiency as of June 30, 2025 | $27,756,255 | Worsened from $24,733,636 at December 31, 2024, highlighting severe short-term liquidity issues. |
| Accumulated deficit as of June 30, 2025 | $103,288,194 | Increased from $101,184,142 at December 31, 2024, indicating persistent unprofitability. |
| Cash used in operating activities for six months ended June 30, 2025 | $1,047,844 | Increased from $976,445 in 2024, showing continued cash burn from operations. |
Frequently Asked Questions
What are the latest SEC filings for Cannapharmarx, Inc. (CPMD)?
Cannapharmarx, Inc. has 17 recent SEC filings from Feb 2024 to Dec 2025, including 8 8-K, 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CPMD filings?
Across 17 filings, the sentiment breakdown is: 2 bearish, 15 neutral. The dominant sentiment is neutral.
Where can I find Cannapharmarx, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cannapharmarx, Inc. (CPMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cannapharmarx, Inc.?
Key financial highlights from Cannapharmarx, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CPMD?
The investment thesis for CPMD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cannapharmarx, Inc.?
Key executives identified across Cannapharmarx, Inc.'s filings include Elliot Zemel.
What are the main risk factors for Cannapharmarx, Inc. stock?
Of CPMD's 15 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Cannapharmarx, Inc.?
Forward guidance and predictions for Cannapharmarx, Inc. are extracted from SEC filings as they are enriched.